BIOLOGY
纳安生物
NANOLATTIX BIOTECHNOLOGY CO., LTD.
Founded in 2016 by Dr. Qu Zhican, a Johns Hopkins University-trained scientist, Nanolattix Biopharmaceuticals specializes in innovative anticancer biologics and companion diagnostics, with a strong focus on antibody-drug conjugates (ADCs). The company has established its proprietary Nanolattix Bio-Lattix R&D Platform, which comprises three key components:
Discovery of tumor-specific drug targets and screening of high-affinity antibodies;
Development of injectable and non-injectable ADC therapeutics;
Research on companion diagnostics for cancer treatment and detection.
Nanolattix's lead candidate, T320-ADC, targets multiple aggressive solid tumors, including pancreatic, lung, cervical, and colorectal cancers. Notably, it has received Orphan Drug Designation (ODD) from the U.S. FDA for pancreatic cancer and has secured Investigational New Drug (IND) approvals from both the FDA and Australia's TGA. Additionally, China's CDE has accepted its clinical trial application, and the drug is now undergoing trials in collaboration with the National Cancer Center/Chinese Academy of Medical Sciences.
Over the next three years, Nanolattix aims to advance multiple ADC drugs through development and commercialization, alongside their companion diagnostics. T320-ADC stands out for its precision targeting of solid tumors, backed by full intellectual property rights and strong druggability. This breakthrough not only fills a critical gap in China's ADC pipeline but also elevates the country's global competitiveness in ADC innovation.
Beyond T320-ADC, Nanolattix is expanding its pipeline with next-generation biologics, including bispecific ADCs and nanobody-based ADCs, leveraging its cutting-edge biopharmaceutical technology platform to drive future breakthroughs in oncology.
